Get the latest tech news
A New HIV Prevention Strategy Sparks Excitement - and Protests Over Cost
"Lenacapavir is not a new drug," reports NPR. "It's been approved by the FDA in the United States for multi-drug resistant HIV treatment since 2022." But instead of treating HIV, what if it were used for preventing infections? The treatment consists of a twice-yearly injection... Early trial r...
This treatment offers an alternative to the current standard of core for HIV prevention efforts for over a decade: taking a pill like Truvada every day... This would allow for manufacturing of generic versions of the drug at a fraction of the cost... [A] group of Médecins Sans Frontières activists gathered at AIDS 2024 and called for an "immediate global action to break Gilead's monopoly on lenacapavir." Gilead is developing a robust direct voluntary licensing program to expedite access to those versions of lenacapavir in high-incidence, resource-limited countries.
Or read this on Slashdot